Disease specific mortality in patients with low risk bladder cancer and the impact of cystoscopic surveillance

Journal of Urology

Volumn 189, Issue 3, 2013, Pages 828-833

  Linton, Kate D ^a   Rosario, Derek J ^a   Thomas, Francis ^a   Rubin, Naomi ^a   Goepel, John R ^b   Abbod, Maysam F ^a   Catto, James W F ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

cystoscopy; Great Britain; risk; urinary bladder; urinary bladder neoplasms

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SIZE; COMPARATIVE STUDY; CYSTOSCOPY; DISEASE SPECIFIC MORTALITY; DYSPLASIA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIMARY TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR GROWTH; TUMOR RECURRENCE;

AGED; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; CYSTOSCOPY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; MALE; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 84873722579     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.09.084     Document Type: Article

References (22)

1. A. Jemal, F. Bray, M.M. Center Global cancer statistics CA Cancer J Clin 61 2011 69
2. J.W. Catto, S. Miah, H.C. Owen Distinct microRNA alterations characterize high and low grade bladder cancer Cancer Res 69 2009 8472
3. P. Mariappan, G. Smith A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database J Urol 173 2005 1108
4. R.J. Sylvester, A.P. van der Meijden, W. Oosterlinck Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 2006 466
5. K.D. Sievert, B. Amend, U. Nagele Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 27 2009 295
6. M.F. Botteman, C.L. Pashos, A. Redaelli The health economics of bladder cancer: a comprehensive review of the published literature Pharmacoeconomics 21 2003 1315
7. V.K. Sangar, N. Ragavan, S.S. Matanhelia The economic consequences of prostate and bladder cancer in the UK BJU Int 95 2005 59
8. R.R. Hall, M.K. Parmar, A.B. Richards Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy BMJ 308 1994 257
9. M.S. Soloway Expectant treatment of small, recurrent, low-grade, noninvasive tumors of the urinary bladder Urol Oncol 24 2006 58
10. V. Hernández, M. Alvarez, E. de la Peña Safety of active surveillance program for recurrent nonmuscle-invasive bladder carcinoma Urology 73 2009 1306
11. O.N. Gofrit, D. Pode, A. Lazar Watchful waiting policy in recurrent Ta G1 bladder tumors Eur Urol 49 2006 303
12. J.W. Catto, D.J. Rosario The road to cystectomy: who, when and why? Eur Urol EAU Update Series 3 2005 171
13. B.K. Hollenbeck, Z. Ye, R.L. Dunn Provider treatment intensity and outcomes for patients with early-stage bladder cancer J Natl Can Inst 101 2009 571
14. J.M. Hollingsworth, Y. Zhang, S.L. Krein Understanding the variation in treatment intensity among patients with early stage bladder cancer Cancer 116 2010 3587
15. M. Babjuk, W. Oosterlinck, R. Sylvester EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update Eur Urol 59 2011 997
16. S. Holmäng, H. Hedelin, C. Anderström Recurrence and progression in low grade papillary urothelial tumors J Urol 162 1999 702
17. G.R. Prout Jr, B.A. Barton, P.P. Griffin Treated history of noninvasive grade 1 transitional cell carcinoma National Bladder Cancer Group J Urol 148 1992 1413
18. F. Thomas, A.P. Noon, N. Rubin Comparative outcomes of primary, recurrent and progressive high-risk non-muscle invasive bladder cancer Eur Urol 63 2013 145
19. G.H. Lyman, N.M. Kuderer, S.J. Freedland Does treatment intensity matter in superficial bladder cancer? Consensus, clinical practice, and confounding J Natl Can Inst 101 2009 543
20. E. Grunfeld, A. Gray, D. Mant Follow-up of breast cancer in primary care vs specialist care: results of an economic evaluation Br J Can 79 1999 1227
21. F. Rodriguez-Moranta, J. Salo, A. Arcusa Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial J Clin Oncol 24 2006 386
22. B.G. Volkmer, R. Kuefer, G.C. Bartsch Jr Oncological followup after radical cystectomy for bladder cancer - is there any benefit? J Urol 181 2009 1587